Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V

Executive Summary

Congress is not expected to pile as many new responsibilities on FDA in the upcoming Prescription Drug User Fee Act reauthorization as in 2007’s FDA Amendments Act.

You may also be interested in...



Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”

Draft guidance from FDA would adopt the International Conference on Harmonization’s periodic benefit-risk evaluation reports, which will offer sponsors the opportunity to provide updates on benefit information along with safety signals to the regulatory authorities.

Congress Mulls Adding “Economic Growth” To FDA Mission Statement

As PDUFA hearings start, Commissioner Hamburg says considering the jobs affected by the approval or denial of an application would be difficult and inappropriate. Rep. Rogers and Sen. Coats author bills to require changing FDA’s mission statement in program renewal.

Congress Mulls Adding “Economic Growth” To FDA Mission Statement

As PDUFA hearings start, Commissioner Hamburg says considering the jobs affected by the approval or denial of an application would be difficult and inappropriate. Rep. Rogers and Sen. Coats author bills to require changing FDA’s mission statement in program renewal.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel